Market closed

X4 Pharmaceuticals/$XFOR

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About X4 Pharmaceuticals

X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Ticker

$XFOR
Trading on

Industry

Biotechnology

Employees

143

XFOR Metrics

BasicAdvanced
$104M
Market cap
-
P/E ratio
-$0.09
EPS
0.39
Beta
-
Dividend rate
$104M
0.39
$1.60
$0.26
5.3M
4.887
4.65
129.117
131.167
-15.67%
-46.55%
-26.35%
108.927
1.73
3.21
-0.92
-88.14%
-71.24%

What the Analysts think about XFOR

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for X4 Pharmaceuticals stock.

XFOR Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

XFOR Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $XFOR

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for X4 Pharmaceuticals stock?

X4 Pharmaceuticals (XFOR) has a market cap of $104M as of December 22, 2024.

What is the P/E ratio for X4 Pharmaceuticals stock?

The price to earnings (P/E) ratio for X4 Pharmaceuticals (XFOR) stock is 0 as of December 22, 2024.

Does X4 Pharmaceuticals stock pay dividends?

No, X4 Pharmaceuticals (XFOR) stock does not pay dividends to its shareholders as of December 22, 2024.

When is the next X4 Pharmaceuticals dividend payment date?

X4 Pharmaceuticals (XFOR) stock does not pay dividends to its shareholders.

What is the beta indicator for X4 Pharmaceuticals?

X4 Pharmaceuticals (XFOR) has a beta rating of 0.39. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.